Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Amadora, Portugal Clinical Trials

A listing of Amadora, Portugal clinical trials actively recruiting patients volunteers.

RESULTS

Found (13) clinical trials

Pregnancy Registry Trial

The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to Gilenya before (up to 8 weeks before last menstrual period) and during pregnancy in routine clinical practice. ...

Phase N/A

1.5 miles

Learn More »

Sonographic Evaluation of Fetal Growth in the Third Trimester of Low-risk Pregnancy: a Randomized Trial

The population to include in this study corresponds to the low-risk pregnant women with surveillance at the Prenatal Consultation or referenced by the Primary Care units to the Department of Obstetrics & Gynecology of Hospital de Santa Maria. The screening method for detection of fetuses at risk of fetal growth ...

Phase N/A

3.5 miles

Learn More »

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer

A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2. MCLA-128 is given in combinations in two metastatic breast cancer (MBC) populations, HER2-positive/amplified (Cohort 1) and Estrogen Receptor-positive/low ...

Phase

4.45 miles

Learn More »

Pre- Versus Postoperative Accelerated Partial Breast Irradiation

Patients will undergo a partial accelerated breast irradiation pre-or postoperative of 5 x 5.7 Gy

Phase N/A

4.45 miles

Learn More »

The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

Phase

4.45 miles

Learn More »

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+ HER2- Advanced Breast Cancer

QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib (Kisqali Prescribing Information, Investigator Brochure). The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule. The purpose of the study is to explore whether a reduced dosing ...

Phase

4.45 miles

Learn More »

Role of Intrapartum Ultrasound in Instrumental Delivery

Investigators will perform a multicentric randomized controlled trial comparing the effect of transabdominal and transperineal ultrasound in pregnant women in the second stage of labor, in whom it was decided an operative delivery. Our objective is to evaluate the impact of intrapartal ultrasound measurements, as an auxiliary to clinical evaluation, ...

Phase N/A

5.21 miles

Learn More »

Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer

EARLY-HEART is a multicentre prospective cohort study that will include 250 female primary breast cancer cases aged 40-75 years treated with postoperative radiotherapy (RT) alone after breast-conserving surgery using modern planning-CT based RT technologies and followed for 2 years after RT in one of the 5 participating hospitals. In addition ...

Phase N/A

5.21 miles

Learn More »

Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis

In a randomized controlled non-blind trial, low-risk women with singleton term pregnancies and a negative Group B Streptococcus culture presenting with PROM are randomly assigned to group A (immediate induction with antibiotic prophylaxis), group B (immediate induction without antibiotic prophylaxis) or group C (delayed induction with antibiotic prophylaxis).

Phase N/A

5.21 miles

Learn More »

Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Duration of the study, per patient, will include eligibility period (screening period) of up to 4 weeks (28 days), treatment period (at least 1 cycle [28 days] of study treatment), and end of treatment (EOT) visit after the last study treatment administration (i.e. at least 30 days post last treatment ...

Phase

5.21 miles

Learn More »